Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Allen Mooney & Barnes Investment Advisors LLC

Allen Mooney & Barnes Investment Advisors LLC decreased its position in Bristol-Myers Squibb (NYSE:BMY) by 9.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 32,793 shares of the biopharmaceutical company’s stock after selling 3,307 shares during the period. Allen Mooney & Barnes Investment Advisors LLC’s holdings in Bristol-Myers Squibb were worth $1,855,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in BMY. Fifth Third Wealth Advisors LLC grew its position in Bristol-Myers Squibb by 6.4% in the fourth quarter. Fifth Third Wealth Advisors LLC now owns 15,928 shares of the biopharmaceutical company’s stock worth $901,000 after acquiring an additional 960 shares during the period. Pines Wealth Management LLC purchased a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $235,000. SeaCrest Wealth Management LLC increased its position in shares of Bristol-Myers Squibb by 13.8% during the fourth quarter. SeaCrest Wealth Management LLC now owns 24,101 shares of the biopharmaceutical company’s stock valued at $1,363,000 after acquiring an additional 2,927 shares during the last quarter. Accurate Wealth Management LLC boosted its position in shares of Bristol-Myers Squibb by 47.0% during the 4th quarter. Accurate Wealth Management LLC now owns 6,140 shares of the biopharmaceutical company’s stock worth $343,000 after purchasing an additional 1,963 shares during the period. Finally, 626 Financial LLC raised its position in Bristol-Myers Squibb by 7.5% in the fourth quarter. 626 Financial LLC now owns 10,053 shares of the biopharmaceutical company’s stock valued at $569,000 after purchasing an additional 699 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Up 0.7 %

Shares of NYSE:BMY opened at $55.73 on Wednesday. The firm has a 50 day simple moving average of $57.44 and a 200-day simple moving average of $51.76. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $61.08. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83. The company has a market capitalization of $113.03 billion, a PE ratio of -15.52, a P/E/G ratio of 15.20 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.31. The firm had revenue of $11.89 billion during the quarter, compared to analysts’ expectations of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. Bristol-Myers Squibb’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same period in the previous year, the company earned $2.00 earnings per share. On average, equities analysts predict that Bristol-Myers Squibb will post 0.93 EPS for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be given a dividend of $0.62 per share. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. The ex-dividend date is Friday, January 3rd. This represents a $2.48 annualized dividend and a yield of 4.45%. Bristol-Myers Squibb’s payout ratio is -69.08%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on BMY shares. Citigroup lifted their price objective on Bristol-Myers Squibb from $55.00 to $60.00 and gave the company a “neutral” rating in a research note on Tuesday, November 12th. Cantor Fitzgerald reiterated a “neutral” rating and set a $50.00 price target on shares of Bristol-Myers Squibb in a research note on Friday, October 18th. TD Cowen raised their price objective on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a research note on Monday, October 7th. Wolfe Research started coverage on shares of Bristol-Myers Squibb in a research note on Friday, November 15th. They set a “peer perform” rating on the stock. Finally, BMO Capital Markets boosted their price target on shares of Bristol-Myers Squibb from $57.00 to $61.00 and gave the stock a “market perform” rating in a research note on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus target price of $56.27.

Insider Buying and Selling at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 1,830 shares of the company’s stock in a transaction on Friday, November 1st. The shares were bought at an average cost of $54.67 per share, for a total transaction of $100,046.10. Following the completion of the purchase, the executive vice president now owns 62,109 shares in the company, valued at $3,395,499.03. This trade represents a 3.04 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Phil M. Holzer sold 700 shares of the stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $55.62, for a total transaction of $38,934.00. Following the sale, the senior vice president now owns 11,760 shares of the company’s stock, valued at $654,091.20. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. 0.09% of the stock is owned by company insiders.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.